Immuron reports Phase 2 Travelan trial shows safety but misses primary efficacy endpoint
Immuron Limited released data from its Phase 2, randomized, placebo‑controlled study of the oral antibody product Travelan. The trial demonstrated a statistically significant 50% reduction in ETEC‑related adverse events and several secondary benefits, but it failed to meet the primary efficacy endpoint because the placebo attack rate was lower than expected. The company said a larger, adequately powered study will be needed to confirm efficacy.
Why it matters
The results triggered a sell‑off, with the shares closing at $1.04, down 3.70%, and trading at $0.98 in pre‑market, down 5.69%. The missed primary endpoint may delay further development and affect near‑term valuation.
Key facts
- 1Travelan achieved a statistically significant 50% reduction in ETEC challenge‑related adverse events versus placebo (p=0.0001). stocktitan.net
- 2The study showed a 40% reduction in moderate‑to‑severe diarrhea. rttnews.com
- 3Severe diarrhea was reduced by 50% compared with placebo. rttnews.com
- 4All diarrhea cases fell by 44% in the Travelan arm. rttnews.com
- 5Early antibiotic use was reduced by 71% among Travelan recipients. stocktitan.net
- 6More than 80% of participants in both arms seroconverted (IgG/IgA anti‑ETEC) by day 15–29. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.